The 2nd International On-line Symposium "Chronic viral infections and cancer, openings for vaccines"

The 2nd International On-line Symposium

“Chronic viral infections and cancer, openings for vaccines”

December 16-17, 2021 www.techvac.org

 

Symposium Co-Chairs

  • Dr Maria Isaguliants, Riga Stradins University, Latvia; Karolinska Institutet, Sweden; National Center for Epidemiology and Microbiology named after N.F. Gamaleya, and Peoples' Friendship University of Russia, Moscow, Russia;
  • Dr Franco Buonaguro, Molecular Biology and Viral Oncology, Department of Experimental Oncology, Istituto Nazionale Tumori Fond Pascale, Naples, Italy;

 

Program Committee

  • Dr Birke Bartosch, INSERM Research Director, Cancer Research Center of Lyon, France;
  • Dr Franco Buonaguro, Molecular Biology and Viral Oncology, Department of Experimental Oncology, Istituto Nazionale Tumori Fond Pascale, Naples, Italy;
  • Dr Alexander Ivanov, Engelhardt Institute of Molecular Biology, Moscow, Russia;
  • Dr Maria Isaguliants, Riga Stradins University, Latvia; Karolinska Institutet, Sweden; National Center for Epidemiology and Microbiology named after N.F. Gamaleya, and Peoples' Friendship University of Russia, Moscow, Russia;
  • Dr Ujjwal Neogi, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

 

Organizing Committee

  • Dr Maria Isaguliants, Associate Professor of Immunology, Riga Stradins University, Latvia, Karolinska Institutet, Sweden, National Center for Epidemiology and Microbiology named after N.F. Gamaleya, and Peoples' Friendship University of Russia, Moscow, Russia 

    ;

  • Dr Ivan Trotsenko, Peoples' Friendship University of Russia, Moscow, Russia;
  • Dr Natalia Petrakova, National Center for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia;
  • Ms Darina Prososhina, Monomax Ltd, St Petersburg, Russia;

 

Science field covered by Symposium

Approximately one out of eight human cancers has a viral etiology. Viral cancers present unique opportunities for prophylaxis, diagnosis, and therapy, as demonstrated by the success of HBV and HPV vaccines and HCV antivirals in decreasing the incidence of tumors that are caused by these viruses.

 

For other chronic viral infections and related cancers, problems still dominate over the progress. Prophylactic HPV vaccination does not cure already established infections, urgently requesting development of therapeutic HPV vaccines. Several are in pipeline, but still far from actual application for treatment of HPV-related cancers. Development of HCV vaccines is in progress, but is hampered by HCV variability and absence of longitudinal sterilizing anti-viral response. The success of antiretroviral therapy in controlling HIV-1 replication and immune reconstitution did not lead to significant reduction of HIV-1 associated cancers indicating alternative mechanisms of their development, not connected to immune suppression.

 

Symposium will unravel the progress in the studies of the molecular pathogenesis of chronic viral infections, cover common mechanisms of action of human oncogenic viruses, such as the activity of viral oncoproteins, induction of genomic instability, support of chronic inflammation, and modulation of tumor microenvironment. Special attention will be devoted to virus-induced alterations in the functions of immune system, induction of innate and adaptive immune responses including the relationship between metabolism and the immune response to viral infections, and immunometabolism on the cellular level. In-depth understanding of these processes would create new openings to the design of novel viral vaccines and immunotherapies.

 

Sympoisum program

Sympoisum will be held by Zoom will be divided into 5 sessions, each divided into 2-3 sections.

 

SESSION 1. MOLECULAR PATHOGENESIS OF CHRONIC VIRAL INFECTIONS

Section 1.1 Chronic viral infections and oxidative stress

Section 1.2 Metabolic signatures of chronic viral infections

 

SESSION 2. CHRONIC VIRAL INFECTIONS AND CANCER

Section 2.1 Mechanisms of viral oncogenicity

Section 2.2 Chronic viral infections and genomic instability 

Section 2.3 Viral infections and chronic inflammation 

 

SESSION 3. POSTER PRESENTATIONS (5 min orals)

 

SESSION 4. IMMUNE RESPONSE TO CHRONIC VIRAL INFECTIONS AND CANCER

Section 4.1 Innate and adaptive immunity weak points

Section 4.2 Immunometabolism of chronic viral infections and cancer

 

SESSION 5. APPROACHES TO VIRAL INFECTION AND CANCER CURE 

Section 5.1 Novel viral infection and cancer treatments

Section 5.3 (Re)profiling of immune response with adjuvants

 

Each section will be opened by invited plenary lecture. Plenary lectures will be read by the renown experts in the field of virology, immunology and oncology, see www.techvac.org for the names and topics.  Already in the program are Opening and Closing Lectures, ten invited plenary lectures and eight 15-20 min orals. Additional 20 orals and 20 posters will be selected based on the submitted abstracts by the Programme Committee.

 

Preliminary interest to participate with presentations was expressed by >100 researchers from France, Italy, Germany, Ireland, Sweden, Norway, Latvia, USA, South Africa, South Korea, and Russia. By November 15, 2021 (one month before the event) we have >50 registered participants, most have submitted abstracts for presentations.

 

Publication of conference materials

Program committee will review all submitted abstracts, and select high quality submissions for oral and poster presentation on the Symposium. All accepted abstracts will be published in a special issue of “INFECTIOUS AGENTS AND CANCER”, BMC journal (Springer Nature), Q2 in Infectious Diseases; IF Web of Science 2.7; IF Scopus 4.3 https://infectagentscancer.biomedcentral.com/about edited by Dr Maria Isaguliants and Prof Franco Maria Buonaguro.

 

Program committee will recommend a selection of abstracts for submission as full-length manuscripts to be published in the above journal issue if accepted. Manuscript corresponding to the best oral given by young carrier researcher selected by the Program Committee and successfully passing revision process will be published free of charge.

 

Partners

 

Organizations interested to become partner for this event are advised to contact Organizing Committee to learn more on the potential partner inputs.

 

Sponsor

Bioline (LCC), https://ex.bioline.ru/

 

Managment:

Monomax Congress Service

Address: Sestroretskaya St., Bld 2, St. Petersburg, 197183 Russia

Tel: +7 (812) 335 2055

Fax: +7 (812) 335 2039

E-mail:

Web site: http://monomax.ru/en/

 

Prof. Maria Isaguliants z Riga Stradins University (Łotwa) współpracuje z Katedrą Biofizyki Ogólnej Wydziału Biologii i Ochrony Środowiska Uniwersytetu Łódzkiego od 2016 r. W ramach wspólnie realizowanych projektów międzynarodowych: "Twinning on DNA-based cancer vaccines" (H2020-TWINN-2015 - Twinning), "Nanoparticle Transfer Through Endothelial Barrier” (M-ERA.NET ) oraz „Działania wzmacniające i upowszechniające międzynarodowe partnerstwo Wydziału Biologii i Ochrony Środowiska na rzecz interdyscyplinarnych badań i innowacji Uniwersytetu Łódzkiego” (NAWA APM) prowadzone są badania naukowe, wymiana studencka i doktorancka oraz szkolenia dla młodych naukowców. 

 Zespoły Uniwersytetu Łódzkiego i Riga Stradins University wspólnie przeprowadziły szereg eksperymentów dotyczących zastosowania dendrymerów w medycynie.  Sprawdzono możliwość zastosowania dendrymerów jako adiuwantów zwiększających skuteczność odpowiedzi immunologicznej na szczepionki DNA.  Obecnie prowadzone są badania nad opracowaniem nanosystemów opartych na dendrymerach i nanocząsteczkach złota, które pokonają barierę śródbłonkową, zapewniając skuteczne i specyficzne dostarczanie substancji terapeutycznych do mózgu.  

ZałącznikWielkość
PDF icon Zaproszenie326.2 KB